Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis

Nephrology Dialysis Transplantation

Volumn 21, Issue 9, 2006, Pages 2432-2438

  Lee, Byung Ha ^a   Nam, Hye Yeong ^b   Kwon, Taegun ^a   Kim, Sung Joo ^c   Kwon, Ghee Young ^c   Jeon, Hyun Jung ^a   Lim, Hyun Jung ^b   Lee, Woo Kyoung ^b   Park, Jong Sang ^b   Ko, Jai Young ^d   Kim, Dae Joong ^c  

^a Samsung Medical Center   (South Korea)

^b Seoul National University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Mitech Co   (South Korea)

Author keywords

Access; Graft; Haemodialysis; Paclitaxel; Polytetrafluoroethylene; Stenosis

Indexed keywords

PACLITAXEL; POLITEF; ANTINEOPLASTIC AGENT; BIOMATERIAL; FLUOROCARBON; POLYTETRAFLUOROETHANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOVENOUS FISTULA; ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; GRAFT OCCLUSION; HEMODIALYSIS; IN VITRO STUDY; JUGULAR VEIN; MALE; NONHUMAN; POLITEF IMPLANT; PRIORITY JOURNAL; RANK SUM TEST; SLOW DRUG RELEASE; SWINE; VEIN INTIMA PROLIFERATION; VEIN OCCLUSION; ANIMAL; ARTERIOVENOUS SHUNT; BLOOD VESSEL PROSTHESIS; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; HYPERPLASIA; INSTRUMENTATION; INTIMA; PATHOLOGY; PROSTHESIS; RENAL REPLACEMENT THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD VESSEL PROSTHESIS; COATED MATERIALS, BIOCOMPATIBLE; DISEASE MODELS, ANIMAL; FLUOROCARBON POLYMERS; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; MALE; PACLITAXEL; PROSTHESIS DESIGN; RENAL DIALYSIS; SWINE; TUNICA INTIMA;

EID: 33750119797     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl070     Document Type: Article

References (20)

1. Scribner BH. Lasker Clinical Medicine Research Award. Medical dilemmas: the old is new. Nat Med 2002; 8: 1066-1067
2. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): Performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004; 44: 22-26
3. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000; 36: 68-74
4. Manns B, Tonelli M, Yilmaz S et al. Establishment and maintenance of vascular access in incident hemodialysis patients: A prospective cost analysis. J Am Soc Nephrol 2005; 16: 201-209
5. Roy-Chaudhury P, Kelly BS, Miller MA et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59: 2325-2334
6. Kanterman RY, Vesely TM, Pilgram TK, Guy BW, Windus DW, Picus D. Dialysis access grafts: Anatomic location of venous stenosis and results of angioplasty. Radiology 1995; 195: 135-139
7. Roy-Chaudhury P, Kelly BS, Melhem M et al. Novel therapies for hemodialysis vascular access dysfunction: Fact or fiction! Blood Purif 2005; 23: 29-35
8. Bennett MR. In-stent stenosis: Pathology and implications for the development of drug eluting stents. Heart 2003; 89: 218-224
9. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233
10. Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004; 109: 1942-1947
11. Rotmans JI, Velema E, Verhagen HJ et al. Rapid, arteriovenous graft failure due to intimal hyperplasia: A porcine, bilateral, carotid arteriovenous graft model. J Surg Res 2003; 113: 161-171
12. Kelly BS, Heffelfinger SC, Whiting JF et al. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int 2002; 62: 2272-2280
13. Masaki T, Rathi R, Zentner G et al. Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Kidney Int 2004; 66: 2061-2069
14. Rotmans JI, Pattynama PM, Verhagen HJ et al. Sirolimuseluting stents to abolish intimal hyperplasia and improve flow in porcine arteriovenous grafts: A 4-week follow-up study. Circulation 2005; 111: 1537-1542
15. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645
16. Halkin A, Stone GW. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: A review of the TAXUS trials. J Interv Cardiol 2004; 17: 271-282
17. Park SJ, Shim WH, Ho DS et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348: 1537-1545
18. Matsuda H, Miyazaki M, Oka Y et al. A polyurethane vascular access graft and a hybrid polytetrafluoroethylene graft as an arteriovenous fistula for hemodialysis: Comparison with an expanded polytetrafluoroethylene graft. Artif Organs 2003; 27: 722-727
19. Goldstein LJ, Helfend LK, Kordestani RK. Postoperative edema after vascular access causing nerve compression secondary to the presence of a perineuronal lipoma: Case report. Neurosurgery 2002; 50: 412-413; discussion 414
20. van der Hoeven BL, Pires NM, Warda HM et al. Drug-eluting stents: results, promises and problems. Int J Cardiol 2005; 99: 9-17